Abrdn Healthcare Investors (HQH)

PHILADELPHIA , Sept. 30, 2025 /PRNewswire/ -- The Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF)  (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on September 30, 2025, on a per share basis to all shareholders of record as of September 23, 2025 (ex-dividend date September 23, 2025).

Berkshire Hathaway's purchase of UnitedHealth signals a potential bottom and renewed interest in the struggling healthcare sector. abrdn Healthcare Investors offers a 12.4% yield and trades at a -9.36% NAV discount, making it an attractive entry point. Key holdings in HQH have shown earnings recovery, and sector rotation may favor undervalued healthcare stocks as S&P 500 valuations remain high.

Healthcare spending continues to rise as Americans, on average, are getting older. We utilize funds to generate strong income from a growth-focused sector. Your retirement portfolio can readily pay your way!

HQH offers high yields with a biotech and small/mid-cap tilt, but relies on capital payouts, making it less tax-efficient and more volatile. Active management and venture capital-style investing add agility but increase risk, with portfolio holdings changing frequently and a heavy biotech concentration. Total returns have been uninspiring, with NAV erosion, funding payouts, and sector underperformance, especially compared to broader healthcare funds like BME.

Healthcare CEFs are under pressure from regulatory shifts, but sector defensiveness and discounted valuations can create long-term opportunities. Within the CEF structure, we also have the added benefit that comes with the discount/premium dynamic inherent in the structure. We are looking at two names today that present investors with attractive distributions and that are looking like decently discounted opportunities.

Groundbreaking AI-powered initiatives are set to transform the healthcare landscape, potentially revolutionizing cancer research and healthcare investing. Aberdeen Investments' four healthcare-focused closed-end funds meet various investor needs: THQ/THW for income and stability, HQH/HQL for growth and innovation exposure. Jason Akus, Portfolio Manager and Head of Healthcare Investments with Aberdeen Investments, gives insight into how new innovations may impact investment opportunities.

I maintain my buy rating on HQH for its high 13.6% yield, strong dividend coverage, and efficient healthcare sector diversification. HQH trades at an 8% discount to NAV, offering an attractive entry point compared to peers, despite recent price declines. The fund is well-positioned to benefit from long-term healthcare sector growth, driven by rising spending and health-conscious trends.

HQH offers a compelling mix of high yield and growth exposure to healthcare, trading at a discount to NAV with recent outperformance versus benchmarks. The fund benefits from strong healthcare industry tailwinds—aging populations and innovation—while active management and share buybacks support narrowing the NAV discount. A robust 13.6% market yield and a fair value estimate 36% above current price highlight significant upside, though distribution sustainability must be monitored.

Berkshire Hathaway's portfolio of cash flow generators allows financial independence and opportunistic moves without financing dependencies. The "Income Method" aims to replicate Mr. Buffett's financial independence by prioritizing the generation of income streams from our personal portfolios. We discuss our top picks with yields of up to 15%.

This month we got some increased market volatility, allowing me to put some of my cash pile to work in my closed-end fund portfolio. I also sold out of two positions, as they were starting to become on the more expensive side in terms of discounts/premiums. Adding to my positions regularly every month increases my cash flow annually, and even every month it grows.

Immunize your retirement from market noise with recurring dividends. We discuss two essential sectors for reliable income generation, regardless of economic conditions. Discover our top picks with up to 10% yields.

Innovation, demand, and shortage of providers have kept healthcare inflation significantly higher than the CPI. Regardless of the political scene, the aging U.S. population and rising chronic illnesses are undeniable truths to face. Income investing ensures consistent returns, allowing flexibility in financial planning, despite volatile stock prices.

HQH offers a high dividend yield of 13.6%, making it attractive for income-focused investors, despite potential tax consequences. The fund trades at a 7.86% discount to NAV, presenting a good entry point, especially with anticipated interest rate cuts and increased healthcare spending. HQH's portfolio is heavily concentrated in Biotechnology (64.6%), posing sector-specific risks but also benefiting from projected growth in biotech and healthcare spending.

Closed-end funds offer unique advantages, like buying at discounts and leveraging with institutionally priced debt, making them ideal income-generating vehicles. Cash distributions are key contributors to total return, but it is essential to be sure they are actually covered by fund earnings. Some investors overly prioritize distribution yields, neglecting the importance of considering total return as a whole.

For over 400 years, dividends have been a steady form of capital from the markets to your account. Dividends can generate dependable and powerful paychecks. We discuss two big yields from dependable sectors.

I maintain a sell rating on the abrdn Healthcare Investors fund due to its incongruence with income investing and managed distribution plans. HQH has underperformed the Nasdaq Biotechnology Index and iShares Biotechnology ETF, highlighting its inability to generate alpha versus more tax-efficient alternatives. The fund's high yield is unsustainable, relying on capital gains and potentially forcing premature sales, which is unsuitable for income-oriented investors.